Phase II Study of Gemcitabine plus Docetaxel in Advanced Pancreatic Cancer: A Hoosier Oncology Group Study
Authors:
- Kristen N. GanjooKGKristen N. Ganjoo
- David E. SeitzDSDavid E. Seitz
- Joel PicusJPJoel Picus
- Farid FataFFFarid Fata
- Cindy StonerCSCindy Stoner
- Cynthia CalleyCCCynthia Calley
- Patrick J. LoehrerPLPatrick J. Loehrer
- 1 December 2003
- journal article
- clinical trial
- Published by S. Karger AG in Oncology
- Vol. 65 (3) , 218-223
Abstract
Objective: To determine the response rate, duration of response and survival with weekly gemcitabine plus docetaxel in metastatic or unresectable pancreatic cancer. Methods: Forty patients were enrolled, and 38 patients were evaluable for survival and toxicity. Thirty-seven patients were evaluable for response. Nine patients (24%) had locally advanced disease and 29 (76%) had metastatic disease at the time of enrollment. Median Eastern Cooperative Oncology Group performance status was 1. Patients received gemcitabine 750 mg/m2 i.v. and docetaxel 35 mg/m2 i.v. weekly for 3 out of 4 weeks for a maximum of 6 cycles. Results: Patients received a median of 4 cycles (range 1–6) of chemotherapy. An objective response was obtained in 10 patients (27%) with a median duration of 17 weeks. Median survival was 7 months, and 1-year survival was 19.3%. Eight patients experienced at least one form of grade 4 toxicity and 27 patients experienced at least one type of grade 3 toxicity. Conclusions: The combination of gemcitabine and docetaxel is a well-tolerated regimen with clinical efficacy. The ultimate role of this combination versus single-agent gemcitabine can only be determined by a randomized phase III trial.Keywords
This publication has 4 references indexed in Scilit:
- A Phase I Study of Weekly Gemcitabine and Docetaxel in Patients with Advanced Cancer: A Hoosier Oncology Group StudyOncology, 2002
- A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinomaCancer, 2001
- Combination Gemcitabine and Docetaxel Therapy in Advanced Adenocarcinoma of the PancreasOncology, 2001
- Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative studyBritish Journal of Cancer, 1999